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ABSTRACT: Cardiac thromboembolism attributed to atrial fibrillation 
(AF) is responsible for up to one-third of ischemic strokes. Stroke may be 
the first manifestation of previously undetected AF. Given the efficacy of 
oral anticoagulants in preventing AF-related ischemic strokes, strategies 
of searching for AF after a stroke using ECG monitoring followed by 
oral anticoagulation (OAC) treatment have been proposed to prevent 
recurrent cardioembolic strokes. This white paper by experts from the 
AF-SCREEN International Collaboration summarizes existing evidence 
and knowledge gaps on searching for AF after a stroke by using ECG 
monitoring. New AF can be detected by routine plus intensive ECG 
monitoring in approximately one-quarter of patients with ischemic stroke. 
It may be causal, a bystander, or neurogenically induced by the stroke. AF 
after a stroke is a risk factor for thromboembolism and a strong marker 
for atrial myopathy. After acute ischemic stroke, patients should undergo 
72 hours of electrocardiographic monitoring to detect AF. The diagnosis 
requires an ECG of sufficient quality for confirmation by a health 
professional with ECG rhythm expertise. AF detection rate is a function of 
monitoring duration and quality of analysis, AF episode definition, interval 
from stroke to monitoring commencement, and patient characteristics 
including old age, certain ECG alterations, and stroke type. Markers of 
atrial myopathy (eg, imaging, atrial ectopy, natriuretic peptides) may 
increase AF yield from monitoring and could be used to guide patient 
selection for more intensive/prolonged poststroke ECG monitoring. 
Atrial myopathy without detected AF is not currently sufficient to initiate 
OAC. The concept of embolic stroke of unknown source is not proven 
to identify patients who have had a stroke benefitting from empiric OAC 
treatment. However, some embolic stroke of unknown source subgroups 
(eg, advanced age, atrial enlargement) might benefit more from non–
vitamin K-dependent OAC therapy than aspirin. Fulfilling embolic stroke 
of unknown source criteria is an indication neither for empiric non–
vitamin K-dependent OAC treatment nor for withholding prolonged ECG 
monitoring for AF. Clinically diagnosed AF after a stroke or a transient 
ischemic attack is associated with significantly increased risk of recurrent 
stroke or systemic embolism, in particular, with additional stroke risk 
factors, and requires OAC rather than antiplatelet therapy. The minimum 
subclinical AF duration required on ECG monitoring poststroke/transient 
ischemic attack to recommend OAC therapy is debated.
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Cardiac thromboembolism attributed to atrial fibril-lation (AF) is responsible for up to one-third of isch-emic strokes. The proportion increases with age,1–3 
with an apparent secular trend to increasing prevalence.4 
AF-related strokes are more frequently fatal or disabling 
and have a higher risk of institutionalization in compari-
son with ischemic strokes from other causes.3,4 Patients 
with AF-related strokes are older and more likely are 
women than those experiencing strokes without AF.4
For between 11.5% and 24% of all patients with 
ischemic stroke or transient ischemic attack (TIA), the 
stroke/TIA is the first clinical documentation of AF. It 
is uncovered either on the admission ECG or by ECG 
monitoring after a stroke.5,6 In addition, the majority 
of AF-related strokes can be prevented by oral antico-
agulation (OAC). These observations have been the ra-
tionale behind calls to search for undetected AF after 
a stroke and before a stroke to prevent a recurrent or 
first ischemic stroke.7 After the occurrence of ischemic 
stroke, the need to search for AF becomes even more 
obvious to start optimal secondary prevention. Direct 
evidence on the benefits of OAC initiation in patients 
with a poststroke AF diagnosis is limited.8 However, 
prior stroke in patients who are found to have clinical 
AF is one of the most powerful predictors of a recurrent 
stroke and has been incorporated in the CHA2DS2-VASc 
(congestive heart failure, hypertension, age category, 
diabetes, stroke/TIA/systemic embolism history, sex, 
vascular disease history) score with 2 points.
Searching for unknown AF after a stroke requires a 
defined process of using ECG monitoring of variable 
intensity and duration. An overview of poststroke AF 
monitoring studies is provided in Table I in the online-
only Data Supplement. Variations in the proportion of 
newly identified AF after a stroke are related to tim-
ing, duration, and method of ECG monitoring, patient 
selection,5,6 and the probability of AF being detected 
before a stroke, which has likely increased in recent 
years.4 In patients free of AF who presented with a 
stroke or TIA, a stepwise approach to searching for 
AF using resting ECG, followed by Holter monitoring, 
and, later, 7-day external loop recorders, the AF detec-
tion rate was 14.8%.9 The estimated overall yield of AF 
detection across heterogeneous studies will result in a 
new AF diagnosis in 23.7% (95% CI, 17.2–31.0) of all 
patients after a stroke,5 11.5% (95% CI, 8.9–14.3) in 
a smaller earlier meta-analysis.6 The heterogeneity of 
these data is obvious, highlighting the evolving nature 
of the information available to guide patient selection 
and ECG monitoring intensity in survivors of a stroke.
In this white paper, we summarize existing evidence 
and knowledge gaps on poststroke AF monitoring com-
piled by experts in the field. Key points do not repre-
sent guidelines or formal recommendations but rather 
provide consensus formulations of the AF-SCREEN In-
ternational Collaboration that may help with a better 
understanding of the complex situation and uncertain-
ties about searching for AF after a stroke and provide 
support for decision making in clinical practice. There 
is no uniformly used term for searching for AF after a 
stroke by ECG monitoring, but it is different from popu-
lation screening in asymptomatic individuals. To call it 
screening for AF may therefore not be appropriate. Prior 
reviews and meta-analyses applied the terms “diagno-
sis,” “monitoring,” or “detection” of AF.5,6,10 The AF-
SCREEN International Collaboration proposes the term 
“searching for AF” in secondary prevention. This implies 
an active, targeted process, requiring a poststroke AF 
search and electrocardiographic monitoring.7 These lat-
ter terms will therefore be used in the white paper.
PATHOPHYSIOLOGY OF STROKE IN AF
AF occurs when electrophysiological triggers act on a 
vulnerable atrial substrate,11 eg, an atrial myopathy de-
termined by genetic, age-, lifestyle-, and disease-relat-
ed dysfunction. Atrial myopathy can be a manifestation 
of a more general cardiomyopathy.12 Once AF begins, it 
leads to further atrial remodeling, thus worsening atrial 
cardiomyopathy.11 It is well established that fibrillation 
of the atria causes blood stasis, endothelial dysfunc-
tion, hypercoagulability, systemic inflammation, and 
thus an increased risk of thromboembolism.13 Change 
in rhythm from AF to sinus, whether spontaneous or 
through cardioversion, temporarily increases the risk of 
cardioembolic stroke.14,15
There are alternative hypotheses for AF occurrence af-
ter a stroke. In one, AF may be just an innocent bystand-
er. Given the shared cardiovascular risk factors, in par-
ticular, older age, stroke and AF may coincide in patients 
with concurrent small and large vessel atherosclerosis 
in the brain and cervicocranial vasculature.16,17 In those 
cases, AF may be only a comorbidity. This hypothesis is 
supported by the finding that, in ≈15% of all strokes 
with prevalent AF, the stroke etiology does not appear to 
be secondary to AF,18 and maintenance of sinus rhythm 
by a rhythm control strategy does not necessarily show a 
strong reduction in stroke rate.19 Whether maintenance 
of sinus rhythm by a rhythm control strategy in AF is as-
sociated with a reduction in stroke rate has not been 
proven by a prospective randomized controlled trial.19 
Similarly, ≈10% of patients with lacunar stroke (ie, isch-
emic stroke as a result of small vessel disease) also have 
AF.16,20 In a second hypothesis, the stroke itself causes 
AF by affecting central autonomic pathways, possibly 
when the insula, frontal regions, or the brainstem are 
affected. However, recent data show no clear relation 
between specific acute infarct location and poststroke 
AF, even after adjusting for infarct size.21 Nevertheless, 
short, self-limiting AF episodes are observed after hem-
orrhagic strokes, which are unlikely to have a cardioem-
bolic cause.22
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In young, fit patients with structurally normal hearts 
and AF, but no other additional stroke risk factors, the 
risk of stroke is only mildly increased,23 indicating that 
AF alone is not a strong enough risk factor to warrant 
treatment with anticoagulation. In paroxysmal subclini-
cal AF detected by implanted devices, the temporal rela-
tion between AF episodes and first-ever stroke is weak 
in most cases,24–26 and stroke rates are lower than in 
patients with clinically detected AF, although there is 
a temporal relation within 5 days of AF shown in one 
study.15 The TRENDS study (A Prospective Study of the 
Clinical Significance of Atrial Arrhythmias Detected by 
Implanted Device Diagnostics) and the ASSERT study 
(Asymptomatic Atrial Fibrillation and Stroke Evaluation 
in Pacemaker Patients and the Atrial Fibrillation Reduc-
tion Atrial Pacing Trial) demonstrate that ischemic stroke 
might occur without episodes of atrial tachyarrhythmias 
or AF in the past 30 days, and, in many cases, within the 
6 months before stroke. AF is often detected only after 
the occurrence of stroke. However, there does appear to 
be a relation between the load or burden of subclinical 
AF and stroke: AF burden >5.5 hours/day or episodes 
lasting >24 hours are associated with higher first-ever 
stroke risk.25–27 Whether this relation holds true for AF 
detected after a stroke is not fully understood.
Markers of abnormal atrial tissue substrate and elec-
trical changes are associated with stroke, particularly 
embolic stroke.28,29 This observation indicates that AF 
may not be the sole or even necessary cause for throm-
boembolism. Many of the atrial tissue changes predis-
posing to AF-structural dilatation, myocyte and endo-
thelial dysfunction, fibrosis, and inflammation plausibly 
play a role in thrombus formation. Thus, left atrial 
thromboembolism likely involves a complex interplay 
of systemic cardiovascular risk factors, atrial tissue sub-
strate, and arrhythmia (Figure 1). AF may be a strong 
marker of atrial myopathy.25 An exact quantitation of 
atrial myopathy is not yet available in routine clinical 
practice. Once AF occurs, it further increases thrombo-
embolic risk by impairing atrial contractile function and 
blood flow and worsening the underlying atrial myopa-
thy. It has remained difficult to clearly characterize atrial 
myopathy or define whether it is part of a more gener-
alized cardiomyopathy, in part, related to the complex 
and heterogeneous etiology of AF. In a 2016 consen-
sus paper, atrial cardiomyopathy was defined as “any 
complex of structural, architectural, contractile or elec-
trophysiological changes affecting the atria with the 
potential to produce clinically relevant manifestations,” 
which applies to AF and stroke.30
For all these reasons, the mechanistic relation be-
tween AF and stroke requires a more complex theo-
retical framework. The potential clinical consequences 
are that it may be possible to tailor the intensity and 
duration of poststroke AF search by assessing atrial 
substrate, eg, by echocardiography,31 electrocardiogra-
Figure 1. Competing and synergistic mechanisms of atrial myopathy and atrial fibrillation in ischemic stroke. 
RAAS indicates renin-angiotensin-aldosterone system; and TIA, transient ischemic attack.
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phy,32 cardiac magnetic resonance imaging, computed 
tomography, or blood biomarkers to understand atrial 
structure and function, degree of fibrosis, and cardiac 
stress. Furthermore, assessment of atrial myopathy may 
complement a poststroke AF search when investigating 
stroke etiology and determining treatments for second-
ary stroke prevention.33 In the future, it might even be 
possible to titrate the intensity of antithrombotic thera-
py based on the severity of atrial myopathy, but this rep-
resents a key knowledge gap requiring further research. 
To date, the prescription of oral anticoagulants after a 
stroke remains dependent on documentation of AF in 
daily practice, and the causal chain of Virchow’s triad 
and left atrial thrombus formation, the most common 
reason for stroke in AF.
DEFINITIONS: ATRIAL ARRHYTHMIAS 
AND AF
AF is currently defined as an irregularly irregular rhythm 
without clear P waves on a surface ECG with a dura-
tion arbitrarily designated at ≥30 sec or a standard 12-
lead ECG. Whereas computerized ECG interpretation 
may support preselection of abnormal ECGs, the AF di-
agnosis should be made or confirmed by a health pro-
fessional experienced in ECG reading. Shorter episodes 
have been termed supraventricular or atrial runs, atrial 
tachycardia, or micro-AF, depending on the rate.34 The 
surface ECG can be recorded by standard 12-lead elec-
trocardiography, by precordial or limb leads, by hand-
held lead 1 rhythm strips, or by wearable devices such 
as Holter monitors or skin adhesive patches. For im-
planted cardiac devices that have an atrial lead, AF is 
detected as atrial high-rate episodes but must be con-
firmed as being truly AF by the inspection of intracar-
diac electrograms. Similarly, implantable cardiac moni-
tors (ICMs) produce a single-lead ECG to diagnose AF 
that must be examined to confirm the diagnosis. Be-
cause many of the episodes detected by continuous 
recorders are silent, these have been termed subclinical 
AF.35
DEFINITIONS: STROKE TYPES AND TIA 
POTENTIALLY RELATED TO AF, AND 
MANAGEMENT IMPLICATIONS
Cryptogenic Stroke
Stroke is defined as neurologic dysfunction caused by 
focal brain, spinal cord, or retinal ischemia with symp-
toms typically lasting >24 hours.36 The term “cryptogen-
ic stroke” is defined as a stroke for which no probable 
cause is found, after a thorough diagnostic workup.37 The 
definition was later modified in the TOAST trial (Trial of 
Org 10172 in Acute Stroke Treatment)38 as a brain infarc-
tion that is either not attributable to a source of definite 
cardioembolism, large artery atherosclerosis, small artery 
disease, or a defined rare cause of brain infarction in pa-
tients with competing stroke etiologies. Unfortunately, 
the term also includes strokes in patients with incomplete 
vascular, cardiac, and serologic workup, and patients with 
competing causes of stroke, as well. AF monitoring has 
been performed inconsistently in cryptogenic stroke.
Embolic Stroke of Undetermined Source 
Embolic stroke of undetermined source (ESUS) is a new 
term coined in 2014 to provide a more specific defini-
tion of a cryptogenic stroke by excluding patients with 
competing causes or incomplete diagnostic evaluation. 
ESUS is defined as a nonlacunar brain infarction con-
firmed by imaging, without hemodynamically relevant 
stenosis (≥50% lumen diameter reduction) of supply ar-
teries, and without an apparent cardioembolic source as 
determined by echocardiography and ≥24 hours of  ECG 
monitoring.39,40 The reported frequency of ESUS ranges 
between 9% and 25% of all ischemic strokes, averaging 
17%.39 In general, patients with ESUS are younger and 
have a lower prevalence of cardiovascular risk factors 
than patients with non-ESUS ischemic strokes.39 The av-
erage ischemic stroke recurrence rate after ESUS is 4.5% 
per year, which is comparable to non-ESUS ischemic 
strokes.39,41 According to current guidelines, antiplatelet 
therapy is recommended for secondary stroke preven-
tion in the majority of patients with ESUS.39
The ESUS concept has been criticized for including 
patients with short ECG monitoring duration, thereby 
potentially encompassing many patients with unknown 
Key Point 3
3.  The diagnosis of AF on poststroke monitoring 
requires documentation by an ECG of sufficient 
quality to allow confirmation by a health profes-
sional with expertise in ECG rhythm interpretation.
Key Points 1 and 2
1.   AF is a risk factor for thromboembolism and a 
strong marker for atrial myopathy. In cases of 
ischemic stroke of uncertain cause, signs of atrial 
myopathy can be used to inform decisions on the 
intensity or duration of monitoring for AF.
2.   Signs of atrial myopathy without detected AF are 
not currently sufficient to initiate OAC.
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AF.39 Unfortunately, even in an industrialized country 
such as Canada, 24-hour Holter ECG monitoring for 
AF is completed routinely in only a minority of patients 
with stroke.42 As a result of the short duration of ECG 
monitoring, AF is detected in only 2% to 3% of patients 
following cryptogenic stroke in clinical practice.43,44 
Studies using prolonged continuous cardiac monitoring 
have detected AF during follow up in 23% to 30% of 
patients with ESUS,41,45 showing that paroxysmal (typi-
cally asymptomatic) AF remains undetected in a signifi-
cant proportion of patients after a stroke. Again, data 
for this estimate are heterogeneous and not sufficient 
for a robust number, but it is clear that searching longer 
and harder and using more sophisticated monitoring 
will increase detection rates.5 Given the high prevalence 
of asymptomatic paroxysmal AF after ESUS and the es-
tablished benefits of OAC46 for the prevention of AF-
related cardioembolic stroke, several clinical trials have 
been conducted to determine if the use of a non–vita-
min K antagonist oral anticoagulant (NOAC) was more 
effective than aspirin to prevent recurrent stroke, test-
ing the hypothesis that the presumed embolic etiology 
of ESUS would respond favorably to OAC in comparison 
with aspirin for the prevention of recurrent stroke.47–49 
A corollary was that, if a significant proportion of ESUS 
is related to asymptomatic paroxysmal AF undetected 
by a 24-hour Holter recording, then recurrent strokes 
should respond in the same way.
The 2 largest trials, NAVIGATE ESUS (Rivaroxaban 
Versus Aspirin in Secondary Prevention of Stroke and 
Prevention of Systemic Embolism in Patients with Re-
cent Embolic Stroke of Undetermined Source) and RE-
SPECT ESUS (Dabigatran Etexilate for Secondary Stroke 
Prevention in Patients with Embolic Stroke of Undeter-
mined Source),50,51 did not show a reduction in recur-
rent stroke among all patients with ESUS treated empir-
ically with NOAC in comparison with aspirin. NAVIGATE 
ESUS used a lower daily rivaroxaban dose (15 mg once 
daily) than the 20 mg once daily dose that is effective in 
stroke prevention in patients with AF and normal renal 
function. This may lead to the assumption that recur-
rent strokes in patients with ESUS could have been pre-
vented better by using the standard dose of rivaroxa-
ban. However, using the standard dose of rivaroxaban 
would not have lowered the observed bleeding rate. 
One might argue that the prevalence of undetected AF 
in the trial was rather low or the risk of ischemic stroke 
associated with subclinical AF was comparably low. 
However, analyses are ongoing to explore subgroups 
of patients with ESUS, in whom a strategy of empiric 
anticoagulation may be beneficial. A post hoc analy-
sis from NAVIGATE ESUS suggests that patients with 
an enlarged left atrium (estimated as left atrial diam-
eter >4.6 cm, ≈10% of trial patients) had less recurrent 
ischemic stroke on rivaroxaban than with aspirin, but 
this will require prospective confirmation. Although it 
is plausible that patients with markedly enlarged left 
atria would be at greatest risk of having or develop-
ing AF, it is also postulated that an enlarged left atri-
um and abnormal left atrial substrate may predispose 
to atrial thromboembolism in the absence of AF. This 
concept is being prospectively tested in the ARCADIA 
trial (Atrial Cardiopathy and Antithrombotic Drugs in 
Prevention After Cryptogenic Stroke), which is enrolling 
patients with ESUS and either left atrial enlargement, 
abnormally high P-wave terminal force in ECG lead V1, 
or elevated N-terminal pro B-type natriuretic peptide.49
In the RE-SPECT ESUS trial, there was a trend in favor 
of dabigatran in comparison with aspirin for secondary 
stroke prevention that developed after 1 year of follow-
up, but this was a post hoc exploratory analysis.51 In a 
prespecified secondary analysis, patients >75 years of 
age appeared to derive greater protection against re-
current stroke with dabigatran (many taking the lower 
dose of 110 mg twice daily) versus aspirin. However, 
the overall negative results for the primary outcomes of 
both NAVIGATE ESUS and RE-SPECT ESUS, may reflect 
the heterogeneity of underlying embolic sources and 
composition of emboli (arterial, cardiogenic, or para-
doxical),50,51 only some of which would benefit from 
OAC, plus a relatively short average duration of treat-
ment and follow-up in those trials. Better phenotyping 
may be required to identify subgroups of patients who 
may benefit from OAC.
The concept of ESUS may thus need a revision and 
specification of defined subtypes. Anticoagulation may 
be effective in selected patients without AF but with 
other evidence of atrial myopathy, although random-
ized trial evidence for this is currently lacking.49 Even if 
AF detected during poststroke monitoring after ESUS 
was not the cause for the index stroke, its detection 
should influence the antithrombotic strategy for pre-
vention of recurrent stroke.
Transient Ischemic Attack 
A TIA is defined as a transient episode of neurological 
dysfunction caused by focal brain, spinal cord, or reti-
nal ischemia without acute infarction according to brain 
Key Points 4 and 5
4.  The concept of ESUS has not been proven to identify 
patients with stroke benefitting from OAC. How-
ever, there may be ESUS subgroups (eg, advanced 
age, significant atrial enlargement) that could ben-
efit more from NOAC therapy than from aspirin.
5.  Fulfilling ESUS criteria is neither an indication for 
NOAC treatment nor for withholding prolonged 
ECG monitoring.
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imaging, with symptoms typically lasting <24 hours. 
The updated TIA definition encompasses the absence 
of infarction on brain imaging, because approximately 
one-third of patients with TIAs, according to clinical 
criteria, have magnetic resonance imaging–detected 
diffusion-weighted imaging lesions, indicating ischemic 
stroke.52 The diagnosis of TIA is difficult to validate, and 
TIAs are probably overdiagnosed in clinical practice. TIA 
has rarely been used as an individual inclusion criterion 
or study end point in AF randomized trials, limiting avail-
able evidence regarding TIA in particular. On the basis 
of a pooled analysis of the Dutch TIA Trial and Dutch 
participants of the European Atrial Fibrillation Trial, the 
risk of vascular events or mortality after TIA or minor 
stroke is higher in patients with AF than in patients with 
TIA without AF at enrollment with an adjusted hazard 
ratio of 1.94 (95% CI, 1.47–2.55) for first stroke.53 Ac-
cording to a meta-analysis of the randomized European 
Atrial Fibrillation trial and the Stroke Prevention in Atrial 
Fibrillation III Trial, the annualized rate of recurrent isch-
emic stroke was more than halved by using a vitamin K 
antagonist in comparison with aspirin in patients with 
TIA and AF.54 In comparison with patients with AF who 
have an ischemic stroke (n=551), the annualized rate of 
recurrent ischemic stroke was lower in patients with AF 
with TIA (n=222) before enrollment (7% versus 11% 
using aspirin and 3% versus 4% using anticoagulation, 
respectively). To date, there is no gold standard of ECG 
monitoring after TIA, and the precise yield of prolonged 
monitoring is unknown. Among patients with TIA or 
minor stroke in the multicenter TIA registry.org project, 
9.6% had an AF diagnosis at discharge and ≈13% had 
AF after 5 years of follow-up.55 The proportion of pa-
tients with AF increases steeply with age, with a preva-
lence of >30% in patients ages ≥85 years.56 A systemat-
ic review and meta-analysis revealed a higher rate of AF 
in selected patients with TIA (including older patients, 
intensified testing for arrhythmias before enrollment, or 
presumed cardioembolic/cryptogenic cause), and after 
prolonged duration of continuous ECG recordings.44,57,58 
Although a substantial underdiagnosis of AF in patients 
with TIA may lead to suboptimal secondary stroke pre-
vention in high-risk patients, caution is needed to avoid 
unnecessary ECG monitoring in patients with nonspe-
cific symptoms mimicking TIA.
WHOM TO MONITOR AFTER A 
STROKE
Although the minimum recommended monitoring has 
traditionally been a 24-hour Holter ECG,59,60 the require-
ment for more prolonged ECG monitoring for all patients 
is under consideration. In unselected survivors of stroke 
or TIA, 72-hour Holter monitoring was feasible and de-
tected an additional 1.8% of patients with paroxysmal 
AF in comparison with 2.6% in the first 24 hours.61 
During a median of 64.0 hours, continuous automated 
stroke unit ECG monitoring detected 92.7% of paroxys-
mal AF cases in comparison with only 34.1% in 24-hour 
Holter recordings after ischemic stroke/TIA.62 Therefore, 
an extension to 72 hours of continuous rhythm monitor-
ing appears to be justified and “short-term ECG record-
ing followed by continuous ECG monitoring for at least 
72 hours” is recommended by current ESC guidelines “in 
patients with TIA or ischemic stroke” (class I, level B).63 
However, higher costs incurred by prolonged monitoring 
and the need of logistics for outpatient follow-up have 
hampered broad application despite demonstration of 
long-term cost-effectiveness.64 In particular, in many re-
source-limited regions, prolonged ECG monitoring may 
not be feasible, although at least a single time point ECG 
is feasible and should become a minimal standard.
For selection of patients to undergo more intensive 
monitoring, a number of factors have been proposed. 
Most rely on either enrichment of AF yield during moni-
toring, or increase in likelihood that any AF discovered 
is associated with recurrent stroke. Descriptors include 
age, demographics, simple clinical risk factors such as 
heart failure, stroke severity, and ECG, imaging or blood 
biomarkers, but the most appropriate clinical approach 
has yet to be precisely defined.
Coexisting Cardiovascular Risk Factors 
and Prediction of New AF After a Stroke
Old age and heart failure are the most powerful predictors 
of new AF after ischemic stroke.45,65–67 The CHA2DS2-VASc 
Key Point 7
7.  Patients with ischemic stroke or TIA should have 
continuous ECG monitoring after a stroke for at 
least 72 hours.
Key Point 6
6.  Clinically diagnosed AF after a stroke and TIA is asso-
ciated with a significantly increased risk of stroke or 
systemic embolism, in particular, in the presence of 
additional stroke risk factors. Patients with a recent 
cerebrovascular event and an episode of poststroke 
AF have not been specifically included in random-
ized trials, but the AF-SCREEN expert consensus is 
that OAC therapy (either well-controlled vitamin K 
antagonist or NOAC) is generally preferred for new 
AF detected by ECG monitoring after a stroke or TIA.
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score and most of its individual components are related 
to poststroke AF diagnosis.65,68 Prediction of AF detection 
after a stroke is made more difficult because some risk 
factors associated with incident AF, such as diabetes mel-
litus, are more closely associated with noncardioembolic 
ischemic stroke,69 so diabetes mellitus may actually be 
associated with a lower risk of finding AF after ischemic 
stroke.65 In addition, patients with diabetes mellitus may 
undergo closer clinical scrutiny, so AF may be detected 
before stroke, contributing to the inverse association.69 
Similarly, smoking, which is strongly associated with non-
AF ischemic stroke, exhibits an inverse relation with post-
stroke AF.65,67 Some other characteristics including mitral 
valve disease or a pacemaker or defibrillator implantation 
may also increase the likelihood of finding AF.65 However, 
factors that are more specific for AF as a cause for stroke, 
such as frequent atrial premature beats, heart failure, B-
type natriuretic peptide, and left atrial size or strain, are 
more likely to be consistent predictors of AF in diverse 
populations and settings, because they may reflect the 
atrial myopathy proposed to underlie both AF and cardio-
embolism.
In clinical practice, a decision to recommend pro-
longed poststroke ECG monitoring is not based on any 
established clinical scores, although some have been 
proposed as being predictive of incident AF.70 Table II 
in the online-only Data Supplement outlines predictors 
for AF in the poststroke setting. The studies were per-
formed in populations with stroke and without prior 
known AF. The data presented for the study by Friberg 
et al67 have been reanalyzed to include only new cases 
of AF diagnosed after the stroke event. Figure 2 is a 
suggested schema for improving poststroke AF moni-
toring. Indicators of an elevated poststroke AF detec-
tion rate after a stroke are summarized in Table 1.
Brain Imaging
A multifocal pattern of ischemic brain lesions, a wedge-
shaped cortical/subcortical pattern, or secondary hem-
orrhagic transformation on brain imaging, may suggest 
an embolic origin from the heart or the aortic arch.71 In 
contrast to hemorrhagic stroke, which has no underly-
ing brain ischemia, secondary hemorrhagic transforma-
tion of an ischemic stroke occurs after reperfusion, and is 
more frequently observed in patients with AF. However, 
in a post hoc analysis of the CRYSTAL AF study (Study of 
Continuous Cardiac Monitoring to Assess Atrial Fibrilla-
tion After Cryptogenic Stroke), the detection of a first ep-
isode of AF did not correlate with brain lesion pattern.17 
Although the likelihood of AF detection is comparatively 
low in patients with a lacunar stroke type, ≈10% of pa-
tients with presumed lacunar stroke have AF.16 This is suf-
ficient to recommend a minimum duration of poststroke 
ECG monitoring in such patients.
Cardiac Imaging
Left atrial enlargement,72,73 valvular abnormalities (in par-
ticular, rheumatic mitral valve stenosis or severe mitral 
and tricuspid valve insufficiency), and spontaneous echo-
cardiographic contrast or solid thrombi in the atrium may 
be predictive of the development of AF after a stroke.20 
In addition, left atrial volume index in combination with 
atrial function has been demonstrated to be predictive 
for detection of AF,74 as has low atrial strain, which pro-
vides independent risk stratification for the development 
Figure 2. Algorithm for intensified atrial fibrillation monitoring in ischemic stroke. 
High atrial fibrillation risk refers to several indicators shown in Table 1. Dashed lines indicate that additional rhythm monitoring could be considered. The color 
shading correlates with the strength of evidence (least evidence in light blue color). Right hand arrow indicates the relation between atrial fibrillation yield and time 
after a stroke that monitoring is commenced.
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of new AF over clinical markers.31 It remains to be estab-
lished whether the morphology of the left atrial append-
age itself, which has been related to thromboembolic 
risk, is a relevant predictor of AF detection after a stroke.75
Electrocardiogram
The presence of atrial runs (lasting <30 sec) and ex-
cessive supraventricular ectopic activity are associated 
with an increased probability of AF detection after a 
stroke.57,72 Atrial runs also increase the risk of recurrent 
stroke.78 An algorithm for ECG monitoring has been 
proposed based on the presence of frequent or infre-
quent atrial premature beats.57 P-wave characteristics 
including P-wave axis, duration, terminal force, and dis-
persion, may be predictors of intermittent AF.79,80
Biomarkers
The predictive value of N-terminal pro B-type natriuretic 
peptide or B-type natriuretic peptide measurement for 
AF detection has been highlighted in several stroke co-
horts.77,81 In addition, elevated C-reactive protein, and 
troponin levels, as well, are related to the AF detection 
rate after a stroke.20 These biomarkers are nonspecific 
predictors, being elevated in various comorbidities (car-
diac and noncardiac) and are predictive of various car-
diovascular and noncardiovascular outcomes.
HOW TO MONITOR: METHODS 
AND CLINICAL SIGNIFICANCE OF 
DETECTED AF
Monitoring methods for AF vary according to the device 
used for ECG recording, quality of ECG signal, number of 
leads available, duration and interval of monitoring, time 
of commencement of recording after a stroke, invasive-
ness of the procedure, and methodology and software 
for rhythm analysis (Table I in the online-only Data Sup-
plement). Technological advances have produced novel 
devices that may improve the feasibility, patient comfort, 
and cost-effectiveness of monitoring for AF. In Figure 3, 
a wide spectrum of devices and methods for AF search 
are illustrated from blood pressure monitors and hand-
held devices that can be used by a healthcare provider 
or in a patient-activated intermittent rhythm-monitoring 
strategy, to wearable, nonadhesive dry-electrode belts, 
adhesive patch devices, and implantable loop recorders 
that provide continuous ECG recordings of variable dura-
tions. A full exposition of available monitoring devices is 
beyond the scope of this white paper, and is available in 
a recent review by Zungsontiporn and Link.10
Oscillometric devices to measure blood pressure or 
smartphone photoplethysmographic methods permit 
the detection of an irregular pulse using proprietary al-
gorithms. To confirm a diagnosis of AF, however, these 
devices require an ECG rhythm strip, which is currently 
a significant limitation. Similarly, smartwatches and fit-
ness trackers are capable of determining AF from pulse 
irregularity, and have a similar limitation. Some smart-
watch applications can monitor pulse regularity contin-
uously when the watch is being worn, and even notify 
the patient if possible AF is detected. If an ECG is built 
into the device (eg, Kardia Band and Apple Watch Se-
ries 4), a patient-activated rhythm strip can also be re-
corded when a warning is sent by the watch. If the de-
vices do not provide a confirmatory ECG rhythm strip, 
an additional ECG is required for AF confirmation as 
was the case in the Apple Heart Study.82 Because of the 
increasing availability of smartphones and smartwatch-
es, even in patients after a stroke, they may become an 
attractive alternative to classical ECG rhythm monitor-
ing for prolonged AF search. For smartphone-based or 
other handheld devices providing an ECG rhythm strip 
recording, requested by health professionals, or even 
by patient-activated intermittent recordings, feasibility 
has been shown83; however, the validity of algorithms, 
the accuracy of AF detection, and noninferiority in 
comparison with classical devices for prolonged ECG 
Table 1. Broadly Available Indicators for a Higher Probability of Atrial 
Fibrillation Detection After Ischemic Stroke 
Clinical characteristics
  Older age, ≥75 y
  Cardiovascular risk factors, in particular, heart failure, hypertension
Signs of atrial myopathy20,57,72,73
  Left atrial diameter >46 mm
  Supraventricular extrasystole ≥480/24 h
  Atrial tachycardia ≥20 beats
Biomarkers76,77
  BNP >100 pg/mL
  NT-proBNP >400 pg/mL
Stroke etiology20
  Arterio-arterial embolism; cryptogenic or ESUS; cardiac cause other than 
atrial fibrillation
Patients with high risk of atrial fibrillation (Figure 2) may have several of these 
characteristics. BNP indicates B-type natriuretic peptide; ESUS, embolic stroke 
of undetermined source; and NT-proBNP, N-terminal pro B-type natriuretic 
peptide.
Key Point 8
8.  Cardiac imaging markers, excessive atrial ectopy, 
and blood biomarkers, including natriuretic pep-
tides that are suggestive of atrial myopathy, 
increase the yield of AF detection, and could be 
used to guide the selection of patients for more 
intensive or prolonged poststroke ECG monitoring.
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monitoring needs to be demonstrated for smartwatch 
ECG techniques in studies after a stroke. Low-noise, 
high-quality signals are necessary for the automated 
algorithms to perform well, which is critical, in particu-
lar, when devices are used in elderly patients after a 
stroke with neurological deficits. Therefore, the place 
of smartwatches with or without inbuilt ECGs in the 
poststroke setting remains to be determined.
Table I in the online-only Data Supplement gives an 
overview of studies in poststroke populations with dif-
ferent monitoring methods and the yield of AF. Direct 
comparison between the methods is difficult for the 
following reasons:
1. Poststroke AF prevalence in certain subgroups 
(eg, cryptogenic stroke, ESUS, large artery ath-
erosclerosis, non-AF cardiac source) may be 
higher than in others (eg, lacunar stroke) and 
selection of subgroups will have an impact on AF 
detection rate.
2. Greater efforts made to detect AF during hos-
pitalization after acute ischemic stroke will 
lower the yield of new AF on ECG monitoring 
postdischarge.84
3. The earlier AF monitoring starts after stroke onset, 
the higher the yield of a first episode of AF.
4. The longer and more continuous the monitoring 
postdischarge, the higher the yield of new AF.
5. Quality of ECG analysis relates to AF detection 
rates.
For poststroke AF search, a combination of different ap-
proaches, eg, noninvasive cumulative 72-hour monitor-
ing in all patients, and more prolonged monitoring in 
patients with increased risk of AF, has been proposed.20 
Some studies have used a staged approach to monitor-
ing, with initial resting ECG, followed by Holter moni-
toring in patients free of AF and then an ICM if these 
are negative. Other approaches use a longer duration 
of intermittent patient-activated or even nurse-activated 
monitoring, which may represent a compromise.83 AF 
can be detected in up to one-quarter of patients after a 
stroke if all the phases of ECG surveillance are included.5
Extended Continuous or Intermittent 
Monitoring Other Than 24-Hour Holter 
Recordings
The Find-AF randomized trial85 (Finding Atrial Fibrilla-
tion in Stroke: Evaluation of Enhanced and Prolonged 
Holter Monitoring) analyzed patients with stroke aged 
≥60 years presenting with sinus rhythm and without 
history of AF randomly assigned to standard care (at 
least 24 hours of rhythm monitoring), or 10-day Holter 
ECG at baseline, 3 months and 6 months after the in-
dex stroke, with the second and third Holter being per-
formed in 68% and 65% of patients without prior AF 
diagnosis who remained in the study. The overall value 
of this monitoring method was similar across the whole 
spectrum of stroke etiology, with 14% new AF versus 
Figure 3. Selection of devices across the bandwidth of techniques currently available for atrial fibrillation search. 
An exact quantitation of atrial myopathy is not yet available in routine clinical practice. ICM indicates implanted cardiac monitor.
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5% in the control arm at 6 months. During extended 
follow-up between 6 and 36 months, the control arm 
almost caught up, with significantly more new AF cases 
than in the intervention arm, indicating that short-term 
monitoring detects AF cases that would otherwise be 
diagnosed later.86 Guideline adherence, with 24-hour 
Holter monitoring performed as usual care in 91.4% 
of the control arm, was very high in comparison with 
other studies. A trend for stroke risk reduction was ob-
served with the intensified monitoring strategy. A large-
scale randomized study that is based on this protocol is 
planned, with recurrent stroke as the end point.
Outpatient Cardiac Telemetry
Mobile cardiac outpatient telemetry was designed for 
arrhythmia monitoring in patients outside the hospital 
setting. New or silent AF discovered by short-term out-
patient monitoring ranges from 0% to 24% over a vari-
able length of follow-up (Table I in the online-only Data 
Supplement). The definition of an episode of AF in some 
of these studies is as short as 5 to 30 sec in duration, 
which is below the currently accepted definition of AF 
duration, although recent observational studies indicate 
that the risk of clinical AF is high among subjects with 
AF episodes <30 sec (micro-AF).34 A common observa-
tion in these studies was that a significant proportion 
did not complete the recommended monitoring course.
ICM, Long-Term Wearable Devices, and 
Intermittent Recordings
ICMs usually detect AF by analyzing the irregularity and 
incoherence of successive R-R intervals. Consequently, 
ICMs require a minimum amount of time, typically 2 
minutes, over which rhythm evidence is accrued and 
analyzed. Data from several studies using ICMs after 
cryptogenic stroke are presented in Table I in the online-
only Data Supplement. AF incidence ranges from 16% 
to 33.7% depending on the definition of episode dura-
tion, the duration of monitoring, and the amount of 
monitoring performed before device implantation.
Two pivotal randomized studies explored long-term 
monitoring versus shorter-term monitoring after cryp-
togenic stroke; CRYSTAL-AF43 compared ICM versus 
standard of care in 441 patients (aged ≥40 years) within 
90 days of cryptogenic stroke, and EMBRACE44 (30-Day 
Cardiac Event Monitor Belt for Recording Atrial Fibrilla-
tion After a Cerebral Ischemic Event) studied a 30-day 
wearable monitor versus a repeat 24-hour Holter in 572 
patients (aged ≥55 years) with a cryptogenic stroke or 
TIA within the last 6 months. Both studies showed that 
long-term monitoring is significantly more sensitive than 
standard arrhythmia monitoring for AF identification.
In the CRYSTAL-AF study,43 AF defined as >30 sec 
was detected in 8.9%, 12.4%, and 30.0% patients in 
the ICM arm and 1.4%, 2.0%, and 3.0% patients in 
the standard-of-care monitoring arm at 6, 12, and 36 
months, respectively.43 At the12-month analysis, the 
median time from randomization to AF detection in the 
ICM arm was 84 days, with 79% of these episodes as-
ymptomatic. At 36 months, AF was detected in 30.0% 
in the patients with ICM versus 3.0% of the control 
group.43 Ambulatory monitoring in the control arms of 
CRYSTAL-AF was at the discretion of the treating physi-
cian and resulted in very limited ECG rhythm monitor-
ing: <30% of patients received conventional ECGs, and 
<10% received 24-hour Holter monitoring.
In the EMBRACE study,44 unlike CRYSTAL-AF, trans-
esophageal echocardiography or intracranial vascular 
imaging was not required as part of the stroke workup. 
The primary end point (detection of AF ≥30 sec within 
90 days) was met in 16.1% and 3.2% of patients in the 
event recorder versus control arms, respectively, with AF 
≥2.5 minutes (secondary end point) in 9.9% and 2.5%, 
respectively, indicating that one-third of the episodes 
detected were very brief.
The duration or burden of episodes of subclinical AF 
relevant for an elevated stroke risk is currently debated, 
and may need to be corrected for the duration of the 
monitoring period. From studies of implanted devices 
in patients without a prior stroke, a dose-response as-
sociation exists between AF duration or burden and the 
subsequent risk of stroke,27,87 but there is a significant 
dynamic process of transition from lower to higher AF 
burden, determined principally by the burden of first-
detected AF episodes.88 The implications of high versus 
low burden of AF detected by continuous monitoring 
may differ in patients after a stroke. In the absence of 
evidence, there is consensus among experts to treat as 
significant any episode of AF ≥30 sec detected by con-
tinuous monitoring after a stroke, and prescribe anti-
coagulant prophylaxis. However, the finding of similar 
yield of new AF on ICMs in patients with no stroke his-
tory (ASSERT II [Prevalence of Sub-Clinical Atrial Fibrilla-
tion Using an Implantable Cardiac Monitor], REVEAL-AF 
[Incidence of AF in High Risk Patients], and PREDATE-
AF [Predicting Atrial Fibrillation or Flutter])25,89–91 to that 
seen in CRYSTAL-AF post–cryptogenic stroke, requires 
some rethinking of the implications of prolonged con-
tinuous ECG monitoring after a stroke, and whether 
Key Point 9
9.  The AF detection rate after cryptogenic stroke is 
a function of length of monitoring, the definition 
of duration of AF that constitutes an episode, 
the interval from the index stroke to the start 
of monitoring, the type of stroke, and patient 
characteristics.
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the threshold of AF burden for basing a therapeutic de-
cision differs between the 2 populations.
MANAGEMENT CHANGES WHEN AF IS 
DETECTED AFTER A STROKE
The EMBRACE and CRYSTAL-AF trials indicate that AF de-
tection changes the treatment from antiplatelet to OAC 
therapy in most patients with cryptogenic stroke: OAC 
use increased from 5% to 10% to almost 97% following 
AF detection,43,44 although this may not apply to health-
care settings outside trials. An important limitation of the 
CRYSTAL-AF and EMBRACE trials is that they were not 
designed to demonstrate an improvement in poststroke 
outcome from prescription of OAC to patients with de-
tected AF, but rather, they were set up to determine AF 
detection rate with prolonged or continuous monitoring. 
In the Find-AF randomized trial, all patients with detected 
AF were switched from antiplatelet to OAC therapy, and 
1 year after randomization, 97% remained on anticoagu-
lation.85 Evidence is limited whether OAC rather than an-
tiplatelet therapy in patients with poststroke AF reduces 
the risk of recurrent ischemic stroke, but expert consen-
sus is that OAC therapy is indicated for any documented 
AF episode lasting >30 sec. The results of the ongoing 
MonDAFIS study (Impact of standardized MONitoring for 
Detection of Atrial Fibrillation in Ischemic Stroke) will add 
further evidence, although recurrent stroke is not the pri-
mary outcome measure in this study.84
In patients with AF detected during monitoring and 
an absolute contraindication to OAC, left atrial append-
age occluders could be considered. Although their role 
and benefit in secondary stroke prevention is not de-
fined, multiple randomized trials are ongoing.
POTENTIAL HARMS OF MONITORING
There are several reasons why monitoring for AF after 
a stroke might potentially cause harm. Table III in the 
online-only Data Supplement summarizes potential 
reasons for harms and possible methods to counter-
act each harm. Most harms result from overtreatment 
with OAC and the potentially fatal side-effects of OAC-
related bleeding. As in clinical AF in patients without 
prior stroke, a risk-benefit assessment of OAC should 
be considered for each patient. This certainly favors an-
ticoagulation when sexless CHA2DS2VA score is ≥2. Be-
cause the CHA2DS2VASc score gives 2 points for a prior 
stroke or TIA, the net clinical benefit would be expected 
to be positive for patients with prior stroke or TIA, and 
AF, because all have a score of at least 2.
Another harm is that AF monitoring procedures and 
additional medical workup could result in unnecessary 
further tests and use of healthcare resources. To re-
duce these potential harms, the population that should 
 undergo monitoring, in particular, more intensive con-
tinuous monitoring, should be carefully defined, and 
continuous quality control of the monitoring procedures 
instituted. Appropriate patient information about po-
tential discomfort with ECG monitoring, and emphasiz-
ing the need for anticoagulation in case of AF detec-
tion, is necessary at the time of initiating monitoring. If 
AF was missed during monitoring or the ECG misinter-
preted, patients with AF may not seek medical atten-
tion if AF becomes symptomatic, because the negative 
monitoring could provide a false sense of security. If the 
harms of untreated AF detected during monitoring or 
the benefit of AF treatment have been overestimated, 
this would also distort the risk-benefit of monitoring for 
poststroke AF. Data from a large UK data set of 5555 
ambulatory asymptomatic patients with incidentally de-
tected AF (of whom 9.2% had prior stroke) suggest that 
the risk of stroke at 3 years is similar to that of symp-
tomatic or hospitalized patients with AF, providing the 
rationale for clinical monitoring in specific settings, such 
as after a stroke, with prescription of oral anticoagula-
tion in patients with AF detected during monitoring.92
PATIENT PERSPECTIVE
Although patients, in general, are strongly supportive of 
detection of AF after a stroke, consideration needs to be 
given to comfort of the chosen detection strategy, and to 
subsequent potential referral and treatment recommen-
dations, as well, if AF is detected. Although ambulatory 
Holter ECG monitoring is widely available, poor patient 
compliance can occur, attributable, in part, to the bulky 
size and wired connections to leads. This is a particular 
issue if Holter recordings are continued over a number of 
days. Skin preparation for ECG monitoring can be abra-
sive and irritating, and adhesives can cause allergic reac-
tions, again more of an issue for wearable recorders used 
over a number of days. In a systematic review of patient 
preference for monitoring, it was noted that any chosen 
monitoring device should be compact and simple to op-
erate and maintain.93 The monitoring devices should not 
affect daily behavior such as showering. Although patient 
preference for treatment is of paramount importance, pa-
tient involvement in choice of monitoring strategy rarely 
occurs, yet this may be a key factor in patient compliance.
HEALTH-ECONOMIC ASSESSMENTS
In the absence of randomized trial evidence, all health-
economic studies rely on assumptions of benefit of 
OAC treatment for AF discovered after a stroke. This is 
the main caveat of cost-effectiveness calculations.
A meta-analysis of 4 studies94 of prolonged Holter 
monitoring (2–21 days) following routine poststroke 
telemetry, found an incidence of detected AF 4.9% to 
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7.7% and a calculated incremental cost-effectiveness 
ratio (ICER) of $13 000 per quality-adjusted life-years 
(QALY) gained by identifying patients who benefit from 
anticoagulation. A comparison of 24-hour Holter with 
7-day Holter monitoring found that the longer period 
was associated with greater cost-benefit (ICER €8354/
QALY).95 Prescreening with transthoracic echocardiog-
raphy added no additional cost-benefit. Intermittent 
ECG monitoring using a handheld device for 10 sec 
twice daily for 30 days was found more cost-effective 
(ICER €6458/QALY) than 24-hour Holter monitoring.96
Although longer duration of continuous monitor-
ing increases AF detection, cost-effectiveness needs to 
balance this against the increased cost of the devices, 
implantation, and device monitoring, and the possibil-
ity that short episodes detected late after a stroke on 
continuous recordings do not carry the same risk. In a 
cost-effectiveness analysis of the EMBRACE trial, a strat-
egy of 30-day noninvasive monitoring appeared cost-
effective with an ICER of $2000/QALY in comparison 
with an additional 24-hour Holter. The 7-day or 14-day 
ECG monitoring was cost saving and more effective 
than an additional 24-hour Holter in this analysis.64 The 
CRYSTAL-AF study43 comparing an ICM against usual 
standard of care (ECG and 24-hour Holter monitoring) 
found an ICER of £17 175/QALY.97 The CRYSTAL-AF 
analysis assumed a number needed to implant to pre-
vent one stroke of ≈20, which may be optimistic, and 
does not take into account the low use of conventional 
or Holter recorders in the control arm. It is notable that 
both NAVIGATE ESUS and EMBRACE analyses recruited 
patients on average >1 month from stroke onset. It is 
arguable that less prolonged, less expensive monitoring 
techniques may have more easily detected patients at an 
earlier time point where cardioembolic risk from the AF 
may be higher, and this would impact health-economic 
comparisons of different ECG monitoring strategies.
CURRENT GUIDELINE 
RECOMMENDATIONS
ECG monitoring for AF is recommended in national and 
international guidelines on poststroke care (Table IV in 
the online-only Data Supplement). Apart from a baseline 
ECG, guidelines remain vague regarding length and type 
of monitoring and direction as to which patients should 
undergo more intensified monitoring. The broadest in-
dication for monitoring is given by the 2016 European 
Society of Cardiology AF guidelines that recommend 
AF monitoring for 72 hours in all patients with ischemic 
stroke without known AF. The American Heart Associa-
tion guidelines state that, for patients with TIA or isch-
emic stroke and AF detected by ECG at the time or within 
24 months preceding the presentation, OAC begun with-
in 3 months is deemed superior to aspirin for the pre-
vention of vascular death, stroke, myocardial infarction, 
and systemic embolism, and is therefore recommended. 
The recommendation is based on 225 patients of whom 
78% had persistent/permanent AF and 22% paroxysmal 
AF. For eligibility, AF had to be documented on ECG at 
admission, or in the case of paroxysmal AF, within the 
previous 24 months.98 The guidelines designate class IB 
level of evidence. The Canadian stroke best practice rec-
ommendations suggest prolonged ECG monitoring for at 
least 14 days in selected patients with ischemic stroke/
TIA of undetermined source in whom a cardioembolic 
mechanism is suspected and who would be amenable to 
OAC. They assign an evidence level A. In general, guide-
lines focus on the detection of AF rather than the yield of 
AF from the monitoring technique. The American College 
Table 2. Key Knowledge Gaps in Searching for Atrial Fibrillation After a Stroke
Pathophysiological role of AF detected poststroke: how to determine whether this is a cause of the index stroke, or a bystander, and its association with 
recurrent cardioembolism.
Determine threshold of AF burden poststroke relative to ECG monitoring intensity and duration, associated with an increased risk of recurrent cardioembolic 
stroke requiring anticoagulation, and the relationship of increased risk with timing of ECG monitoring commencement after stroke.
Determine the persistence and recurrence rate of paroxysmal AF first detected in the acute phase of stroke.
Define whether atrial myopathy/cardiomyopathy increases recurrent stroke risk independent of AF. This requires definition, quantitation, and validation of atrial 
myopathy markers, eg, atrial enlargement, atrial ectopy or P-wave morphology, functional imaging, and elevation in blood biomarkers such as NT-proBNP. Test 
use of these markers prospectively to tailor type, intensity, and duration of ECG monitoring for AF detection, and effect of empiric antithrombotic treatment (as 
in the ARCADIA study).
Identify predictors of poststroke AF that could be used to tailor intensified monitoring.
Identify ESUS subgroups with increased cardioembolic risk likely to benefit from empiric OAC treatment without ECG monitoring for AF, and test prospectively.
Define the most effective method, intensity, and duration of rhythm monitoring after ischemic stroke to detect clinically relevant AF.
Define and validate the most cost-efficient method for poststroke AF monitoring in a variety of healthcare systems including those with limited resources and 
limited access to vitamin K antagonist monitoring and NOACs.
Develop pathways and structures for widespread implementation of searching for AF in stroke units and in poststroke care tailored to country-specific resources 
and requirements.
AF indicates atrial fibrillation; ARCADIA, Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke; ESUS, embolic stroke of 
undetermined source;  NOAC, non–vitamin K antagonist oral anticoagulant; NT-proBNP, N-terminal pro B-type natriuretic peptide; and OAC, oral anticoagulation.
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of Chest Physicians 2018 antithrombotic AF guidelines 
have no specific recommendation but discuss continued 
cardiac evaluation (eg, prolonged rhythm monitoring) 
for patients with ESUS. The Australian Heart Founda-
tion and Cardiac Society of Australia and New Zealand 
2018 guideline recommends that, for patients with ESUS, 
longer-term ECG monitoring (external or implantable) 
should be used, whereas the 2019 American Heart As-
sociation/American College of Cardiology/Heart Rhythm 
Society update of the 2014 guideline states that ICM im-
plantation is reasonable to optimize detection of silent 
AF, in patients with cryptogenic stroke in whom external 
ambulatory monitoring is inconclusive.
CONCLUSIONS
In the absence of a prior history of the arrhythmia, AF 
can be detected by ECG monitoring in approximately 
one-quarter of all patients with acute ischemic stroke 
by routine monitoring followed by an intensified or 
prolonged AF search. It may be the cause of the index 
stroke, a bystander, particularly in older patients with 
high cardiovascular comorbidity and risk factor burden; 
or a neurogenically induced, secondary consequence of 
stroke. Atrial myopathy may play a role in thromboem-
bolic risk and is an indicator of increased poststroke AF 
detection rate on ECG monitoring. Monitoring for AF 
poststroke/TIA requires an ECG-based diagnosis. A min-
imum duration of 72 hours of cumulative ECG record-
ing should follow ischemic strokes in patients who do 
not have a prior AF diagnosis. Longer periods of contin-
uous monitoring will detect more AF cases, and a num-
ber of factors could be used to determine the selection 
of patients for more intensive monitoring. Whether the 
duration or burden of AF increases the risk of recurrent 
stroke is debated and is a key knowledge gap (Table 2); 
nevertheless, OAC treatment is often prescribed for any 
AF episode ≥30 sec. At present, there is no evidence 
supporting initiation of OAC therapy in patients with 
markers of atrial myopathy or with cryptogenic stroke 
or ESUS. The diagnosis of AF after a stroke should lead 
to changes in clinical workup, and usually, institution of 
OAC therapy. There are a number of knowledge gaps 
summarized in Table 2. In particular, further evidence is 
needed to establish risk-stratified ECG monitoring strat-
egies that are safe, effective, and cost-effective.
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